EU approves its first vaccine for common respiratory virus RSV

European regulators have approved the region’s first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.

The shot, called Arexvy, is made by British drugmaker GSK and is designed to protect people aged 60 and over.

RSV typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.

The complex molecular structure of the virus and safety concerns with previous vaccine attempts had...